Treatment News : FDA Approves New HIV Drug: Edurant (Rilpivirine)

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 20, 2011

FDA Approves New HIV Drug: Edurant (Rilpivirine)

The U.S. Food and Drug Administration (FDA) has approved a new HIV-fighting non-nucleoside reverse transcriptase inhibitor (NNRTI) called Edurant (rilpivirine). The drug was approved for use as part of a complete treatment regimen for people who haven’t taken antiretroviral (ARV) drugs before.

“Patients may respond differently to various HIV drugs or experience varied side effects. FDA’s approval of Edurant provides an additional treatment option for patients who are starting HIV therapy,” said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

In a study comparing Edurant to another NNRTI—Sustiva (efavirenz)—researchers found that the two drugs were quite similar, with both resulting in undetectable HIV levels after 48 weeks for about 80 percent of those who took the drugs. The FDA noted in its approval announcement, however, that people with high viral loads were more likely to fail Edurant than those taking Sustiva. Also, when people failed treatment, those taking Edurant were more likely to develop resistance to the drugs in their regimen than those taking Sustiva.

Though the most common side effects were similar to those experienced with Sustiva—depression, difficulty sleeping, headaches and rash—people taking Edurant generally had fewer side effects than those on Sustiva.

Edurant’s maker, Tibotec Therapeutics—a division of Centocor Ortho Biotech Inc.—is also partnering with Gilead Sciences to develop a single pill combining Edurant with Gilead’s Truvada (tenofovir plus emtricitabine). Approval of that combination pill is expected within the year.

Search: Edurant, rilpivirine, NNRTI, non-nucleoside reverse transcriptase inhibitor, FDA, FDA approval, Sustiva, efavirenz, depression, sleep, side effects, Edward Cox, Tibotec Therapeutics, Centocor Ortho Biotech


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 1 (of 1 total)    

Don, San Francisco, 2011-05-25 12:54:58
after all these years, why are you - especially this site - talking as if people FAIL the drugs instead of the drugs FAILING people/failing to be effective for some in some cases/etc. years ago, you made a big deal about people not being AIDS victims but people with AIDS, blah, blah, blah, but you continue to use this languaging which totally mischaracterizes the situation. get it right!

comments 1 - 1 (of 1 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    slimcuteguy
    Asheville
    North Carolina


    Heartland4now
    Tacoma
    Washington


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.